Literature DB >> 16344578

Steatosis in chronic hepatitis C: why does it really matter?

T Asselah1, L Rubbia-Brandt, P Marcellin, F Negro.   

Abstract

Hepatic steatosis is a common histological feature of chronic hepatitis C. Various factors are associated with hepatic steatosis, including obesity, high alcohol consumption, diabetes type II, and hyperlipidaemia. These factors may contribute to steatosis in patients with chronic hepatitis C. In humans, hepatitis C virus (HCV) genotype 3 is more commonly associated with steatosis. In vitro studies and the transgenic mouse model have suggested that the HCV core protein (genotype 1) can induce lipid accumulation within hepatocytes. However, what is the relevance of steatosis in chronic hepatitis C? It seems that in certain populations, steatosis may be associated with fibrosis progression and this may be genotype specific. The mechanisms underlying this association are unknown; neither is it clear whether this holds true for all patients or only a subgroup. Indeed, after antiviral treatment, virus related steatosis disappears whereas the host associated steatosis remains unaffected. This review describes and discusses the basic and clinical aspects of the relationship between steatosis and progression of fibrosis, and response to treatment in patients with chronic hepatitis C.

Entities:  

Mesh:

Year:  2006        PMID: 16344578      PMCID: PMC1856395          DOI: 10.1136/gut.2005.069757

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  78 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

Review 2.  AGA technical review on nonalcoholic fatty liver disease.

Authors:  Arun J Sanyal
Journal:  Gastroenterology       Date:  2002-11       Impact factor: 22.682

3.  Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection.

Authors:  Jason M Hui; James Kench; Geoffrey C Farrell; Rita Lin; Dev Samarasinghe; Christopher Liddle; Karen Byth; Jacob George
Journal:  J Gastroenterol Hepatol       Date:  2002-08       Impact factor: 4.029

4.  High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

Authors:  Brian L Bressler; Maha Guindi; George Tomlinson; Jenny Heathcote
Journal:  Hepatology       Date:  2003-09       Impact factor: 17.425

5.  Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C.

Authors:  T Asselah; N Boyer; M-C Guimont; D Cazals-Hatem; F Tubach; K Nahon; H Daïkha; D Vidaud; M Martinot; M Vidaud; C Degott; D Valla; P Marcellin
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

6.  Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

Authors:  I J Hickman; A D Clouston; G A Macdonald; D M Purdie; J B Prins; S Ash; J R Jonsson; E E Powell
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

7.  Contribution of obesity to hepatitis C-related fibrosis progression.

Authors:  Vicente Ortiz; Marina Berenguer; José M Rayón; Domingo Carrasco; Joaquin Berenguer
Journal:  Am J Gastroenterol       Date:  2002-09       Impact factor: 10.864

8.  Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

Authors:  Thierry Poynard; Vlad Ratziu; John McHutchison; Michael Manns; Zachary Goodman; Stefan Zeuzem; Zobair Younossi; Janice Albrecht
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

9.  Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response.

Authors:  Dinesh Kumar; Geoffrey C Farrell; Caroline Fung; Jacob George
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

10.  Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol.

Authors:  Alexander Monto; Judy Alonzo; Jessica J Watson; Carl Grunfeld; Teresa L Wright
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

View more
  106 in total

Review 1.  Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment.

Authors:  Steven D Lidofsky
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

2.  Performance of liver stiffness measurements by transient elastography in chronic hepatitis.

Authors:  Giovanna Ferraioli; Carmine Tinelli; Barbara Dal Bello; Mabel Zicchetti; Raffaella Lissandrin; Gaetano Filice; Carlo Filice; Elisabetta Above; Giorgio Barbarini; Enrico Brunetti; Willy Calderon; Marta Di Gregorio; Roberto Gulminetti; Paolo Lanzarini; Serena Ludovisi; Laura Maiocchi; Antonello Malfitano; Giuseppe Michelone; Lorenzo Minoli; Mario Mondelli; Stefano Novati; Savino F A Patruno; Alessandro Perretti; Gianluigi Poma; Paolo Sacchi; Domenico Zanaboni; Marco Zaramella
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

3.  Elevated plasma sphingomyelin (d18:1/22:0) is closely related to hepatic steatosis in patients with chronic hepatitis C virus infection.

Authors:  J-F Li; F Qu; S-J Zheng; H-L Wu; M Liu; S Liu; Y Ren; F Ren; Y Chen; Z-P Duan; J-L Zhang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-09       Impact factor: 3.267

Review 4.  Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions.

Authors:  Sreedhar Chinnaswamy
Journal:  J Interferon Cytokine Res       Date:  2014-02-20       Impact factor: 2.607

5.  Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells.

Authors:  Baptiste Jammart; Maud Michelet; Eve-Isabelle Pécheur; Romain Parent; Birke Bartosch; Fabien Zoulim; David Durantel
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

6.  Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus.

Authors:  Kohichiroh Yasui; Yuichi Harano; Hironori Mitsuyoshi; Kazuhiro Tsuji; Mio Endo; Tomoaki Nakajima; Masahito Minami; Yoshito Itoh; Yoh Zen; Yasuni Nakanuma; Toshikazu Yoshikawa; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2009-09-30       Impact factor: 7.527

7.  Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation.

Authors:  Ming-Ling Chang; Chau-Ting Yeh; Deng-Yn Lin; Yu-Pin Ho; Chen-Ming Hsu; D Montgomery Bissell
Journal:  BMC Med Genomics       Date:  2009-08-08       Impact factor: 3.063

Review 8.  Nutrigenomics therapy of hepatisis C virus induced-hepatosteatosis.

Authors:  Qing Liu; Stig Bengmark; Shen Qu
Journal:  BMC Gastroenterol       Date:  2010-05-20       Impact factor: 3.067

9.  Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP).

Authors:  Silvia Mirandola; David Bowman; Mahmood M Hussain; Alfredo Alberti
Journal:  Nutr Metab (Lond)       Date:  2010-02-23       Impact factor: 4.169

10.  Retinol supplements antiviral action of interferon in patients with chronic hepatitis C: a prospective pilot study.

Authors:  Naruaki Kohge; Shuichi Sato; Sachiko Hamamoto; Shuji Akagi; Yasushi Uchida; Tatsuya Miyake; Tomoko Mishiro; Kohichiro Furuta; Naoki Oshima; Junnichi Ishine; Yoshiko Takahashi; Norihisa Ishimura; Ryo Fukuda; Shunji Ishihara; Yuji Amano; Yoshikazu Kinoshita
Journal:  J Clin Biochem Nutr       Date:  2009-12-29       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.